Erasca reports RAS cancer drug data after legal threat from Revolution

After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown between the biotechs. And it did ...